SXTP

60 Degrees Pharmaceuticals, Inc. (SXTP) - Q1 2025 Filing Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2025. 60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and marketing of medicines for infectious diseases. Its lead product, ARAKODA® (tafenoquine), is FDA-approved for malaria prevention. The company is currently pivoting its strategy to expand indications for tafenoquine (specifically for babesiosis) and commercialize existing products, following the suspension of a planned COVID-19 study. The company is classified as a non-accelerated filer, smaller reporting company, and emerging growth company.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 162% year-over-year, driven by a 55% increase in product sales volume (1,579 boxes vs. 1,022 boxes) and a significant rise in research revenue ($92,731 vs. $29,631) due to a new contract with the U.S. Army Medical Materiel Development Activity (USAMMDA).
• Operating Expenses: Total operating expenses rose 48% to $2.09 million. General and Administrative (G&A) expenses increased 57% primarily due to higher sales, advertising, promotion, and investor outreach costs, as well as $142,645 in stock-based compensation (compared to $0 in Q1 2024).
• Profitability Shift: The company reported a net loss of $1.88 million in Q1 2025, contrasting with a net income of $428,000 in Q1 2024. The prior year's income was significantly boosted by a $1.74 million gain from the change in fair value of derivative liabilities, whereas Q1 2025 saw only a $5,105 gain in this category.
• Liquidity: Cash balances increased by $1.79 million, primarily due to net proceeds of approximately $1.71 million from two registered direct offerings in January and February 2025.

Guidance, Outlook, and Risks

• Going Concern: Management has concluded that substantial doubt exists regarding the company's ability to continue as a going concern for one year from the date of issuance. The company relies on raising additional capital to fund operations and clinical trials.
• Liquidity Outlook: Based on current projections and recent capital raises, management estimates sufficient funds to remain viable through August 31, 2025, excluding the costs of the planned Phase II study for chronic babesiosis.
• Capital Raises: The company completed two offerings in Q1 2025:
  • January 2025: Sold 204,312 shares and warrants for net proceeds of ~$804,000.
  • February 2025: Sold 300,700 shares and warrants for net proceeds of ~$909,000.
• Operational Updates:
  • First patient enrolled in an expanded access study for babesiosis (NCT06478641).
  • IRB approval received for a new Phase II clinical study for chronic babesiosis (NCT06656351), with enrollment expected in Q3 2025.
  • FDA authorized importation of Kodatef (Australian tafenoquine) to mitigate potential supply disruptions of Arakoda in the U.S.
• Internal Controls: The company identified material weaknesses in internal controls over financial reporting, citing a lack of full-time in-house personnel with technical knowledge for complex transactions and inadequate segregation of duties.

Investor Verification Checklist

• Cash Runway: Verify the company's ability to raise capital before the projected August 31, 2025, liquidity horizon.
• Revenue Concentration: Note that 85% of product revenue comes from a single U.S. distributor and 9% from an Australian distributor; assess dependency risks.
• Derivative Liability: Monitor the $635,725 contingent milestone payment liability to Knight Therapeutics, which could trigger a $10 million payment upon a sale of Arakoda or Change of Control.
• Stock Dilution: Review the impact of recent equity offerings and the 1:5 reverse stock split (effective Feb 2025) on share count and ownership structure.
• Clinical Progress: Track enrollment and results of the new Phase II babesiosis study, which is critical for future revenue expansion beyond malaria prevention.